CINP Perspectives ::: June 2011
- Clinical trials of amyloid-targeting compounds in Alzheimer’s disease (AD) – Is targeting amyloid a worthwile disease-modifying approach in AD?
by Harald Hampel & David Prvulovic
You have to login to participate in the discussion. View discussion guidelines here. All comments will be moderated.
